DATA GRAPHICS | Data Byte
The muscarinic pipeline for neuropsychiatry gets selective
Over half of clinical programs targeting muscarinic receptors for neuropsychiatric symptoms act on specific receptor subtypes
November 23, 2021 2:45 AM UTC
The longstanding interest in muscarinic acetylcholine receptors for psychosis and dementia-related symptoms has been somewhat tempered over the years by the inability to selectively target specific members of the receptor family. That challenge may soon be overcome.
According to BioCentury’s BCIQ database, over half of the 11 muscarinic-acting compounds in clinical development for neuropsychiatric symptoms target specific receptor subsets...